Mutual Termination Agreement dated January 26, 2018, by and between PharmaCyte Biotech, Inc. and Chardan Capital Markets, LLC

EX-10.2 4 pharmacyte_ex1002.htm MUTUAL TERMINATION AGREEMENT

Exhibit 10.2

 

 

 

 

 

VIA EMAIL ONLY

 

January 26, 2018

 

Kerry Propper

Chief Executive Officer

Chardan Capital Markets, LLC

17 State Street

New York, NY 10004

 

Re: Mutual Termination Agreement

 

Dear Mr. Propper:

 

This letter is to confirm that PharmaCyte Biotech, Inc. (“Company”) and Chardan Capital Markets, LLC (“Chardan”) have agreed to mutually terminate the letter agreement between Chardan Capital Markets, LLC (“Chardan”) and the Company dated May 28, 2014, as amended on December 15, 2016 (collectively, “Engagement Agreement”). Chardan agrees that no further fees or warrants are due and payable by the Company to Chardan pursuant to the Engagement Agreement.

 

 

  Sincerely,
   
   
  /s/ Kenneth L. Waggoner                      
  Chief Executive Officer
  President and General Cousel
   
   
   

 

 

Acknowledged and Agreed

 

Chardan Capital Markets, LLC

 

 

By: /s/ George Kaufman                 

Name: George Kaufman

Title: Managing Director